MedTrace Logo

CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial

NCT03732339 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2022-04-29

No results posted yet for this study

Summary

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. The purpose of this clinical trial is to evaluate the predictive value of CTC in neoadjuvant chemotherapy among locally advanced breast cancer patients.

Conditions

  • Locally Advanced Breast Cancer
  • Circulating Tumor Cell

Interventions

DEVICE

GILUPI CellCollector®

Use of GILUPI CellCollector® to detect CTC

Sponsors & Collaborators

  • Beijing Viroad Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Jinsong Lu · RenJi Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-24
Primary Completion
2019-03-11
Completion
2019-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03732339 on ClinicalTrials.gov